Adaptive Biotechnologies (ADPT) said late Monday it has issued $345 million of 0% convertible senior notes due 2031, including the full exercise of an over-allotment option.
Net proceeds were used among others for capped call transactions, share repurchase, and for the repayment of the OrbiMed purchase agreement, the company said in a filing.